Eli Lilly (LLY) director reports 14.525-share buy at $808.96
Eli Lilly (LLY) director reported acquiring 14.525 shares of common stock on 10/20/2025 at $808.96 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly (LLY) director reported acquiring 14.525 shares of common stock on 10/20/2025 at $808.96 per share. The award was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares following the director’s separation from service. After the transaction, beneficial ownership was 55,151.946 shares directly and 758 shares indirectly by trust.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 14.525 | $808.96 | $12K |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
- F2. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who reported the transaction for LLY and what is their role?
What did the LLY director acquire and at what price?
When did the reported LLY transaction occur?
What is the director’s beneficial ownership after the trade?
Does the filing mention indirect ownership details?
AI-generated analysis. How Rhea-AI works. Not financial advice.